CY1124486T1 - Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου - Google Patents

Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Info

Publication number
CY1124486T1
CY1124486T1 CY20211100750T CY211100750T CY1124486T1 CY 1124486 T1 CY1124486 T1 CY 1124486T1 CY 20211100750 T CY20211100750 T CY 20211100750T CY 211100750 T CY211100750 T CY 211100750T CY 1124486 T1 CY1124486 T1 CY 1124486T1
Authority
CY
Cyprus
Prior art keywords
thiazol
substituted
yluminum
benzamides
compounds
Prior art date
Application number
CY20211100750T
Other languages
English (en)
Inventor
Adam James Davenport
Nico Braeuer
Oliver Martin Fischer
Andrea Rotgeri
Antje Rottmann
Ioana NEAGOE
Jens Nagel
Anne-Marie GODINHO-COELHO
Juergen Klar
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124486(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of CY1124486T1 publication Critical patent/CY1124486T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις υποκατεστημένου βενζαμιδίου 1,3-θειαζολ-2-υλίου του γενικού τύπου (Ι) όπως περιγράφονται και ορίζονται στην παρούσα, σε φαρμακευτικές συνθέσεις και συνδυασμούς που περιλαμβάνουν τις εν λόγω ενώσεις και στη χρήση των εν λόγω ενώσεων για την παρασκευή μίας φαρμακευτικής σύνθεσης για τη θεραπευτική αντιμετώπιση ή προφύλαξη από μία πάθηση, συγκεκριμένα από νευρογενή διαταραχή, ως ένας μοναδικός παράγοντας ή σε συνδυασμό με άλλα δραστικά συστατικά.
CY20211100750T 2014-12-09 2021-08-20 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου CY1124486T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196954 2014-12-09
PCT/EP2015/078765 WO2016091776A1 (en) 2014-12-09 2015-12-07 1,3-thiazol-2-yl substituted benzamides

Publications (1)

Publication Number Publication Date
CY1124486T1 true CY1124486T1 (el) 2022-07-22

Family

ID=52015966

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100750T CY1124486T1 (el) 2014-12-09 2021-08-20 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CY20221100217T CY1125083T1 (el) 2014-12-09 2022-03-15 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20221100217T CY1125083T1 (el) 2014-12-09 2022-03-15 Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου

Country Status (41)

Country Link
US (5) US10174016B2 (el)
EP (2) EP3230281B1 (el)
JP (2) JP6544665B2 (el)
KR (2) KR102548799B1 (el)
CN (2) CN107207507B (el)
AR (2) AR102948A1 (el)
AU (1) AU2015359626B2 (el)
BR (1) BR112017012327B1 (el)
CA (1) CA2969952A1 (el)
CL (1) CL2017001488A1 (el)
CO (1) CO2017005742A2 (el)
CR (2) CR20210108A (el)
CU (1) CU24411B1 (el)
CY (2) CY1124486T1 (el)
DK (2) DK3587417T3 (el)
DO (2) DOP2017000137A (el)
EA (2) EA034273B1 (el)
EC (1) ECSP17036253A (el)
ES (2) ES2908822T3 (el)
HR (2) HRP20220371T1 (el)
HU (2) HUE055290T2 (el)
IL (6) IL252665B (el)
JO (1) JOP20150301B1 (el)
LT (2) LT3230281T (el)
MA (2) MA41135B1 (el)
MX (2) MX2020005909A (el)
MY (1) MY192690A (el)
NI (1) NI201700073A (el)
PE (2) PE20220253A1 (el)
PH (1) PH12017501079A1 (el)
PL (2) PL3587417T3 (el)
PT (2) PT3587417T (el)
RS (2) RS63014B1 (el)
SG (2) SG10202012274RA (el)
SI (2) SI3587417T1 (el)
SV (1) SV2017005461A (el)
TN (1) TN2017000244A1 (el)
TW (2) TWI716371B (el)
UA (1) UA120382C2 (el)
UY (1) UY36422A (el)
WO (1) WO2016091776A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3587417T (pt) * 2014-12-09 2022-03-16 Bayer Ag Benzamidas substituídas por 1,3-tiazol-2-ilo
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
CN106588785A (zh) * 2016-12-02 2017-04-26 山东吉田香料股份有限公司 一种乙酰基吡嗪的制备方法
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
SG11202011010YA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MA52616A (fr) * 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
US11883407B2 (en) 2018-10-05 2024-01-30 Shionogi & Co., Ltd. Medicament for the treatment of chronic cough
BR112021006889A2 (pt) * 2018-10-10 2021-07-13 Bellus Health Cough Inc. método para tratar prurido em um mamífero
EP3930722A4 (en) * 2019-02-25 2022-12-28 Bellus Health Cough Inc. TREATMENT WITH P2X3 MODULATORS
BR112021019987A2 (pt) * 2019-04-05 2021-12-07 Syngenta Crop Protection Ag Compostos de diazina-amida pesticidamente ativos
MX2021012290A (es) * 2019-04-11 2021-11-12 Syngenta Crop Protection Ag Compuestos de diazina-amida activos como pesticidas.
WO2020239951A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
CN114222741A (zh) 2019-05-31 2022-03-22 奇斯药制品公司 作为p2x3抑制剂的吡啶并嘧啶类衍生物
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
AU2021282039A1 (en) * 2020-05-25 2022-12-01 The National Institutes of Pharmaceutical R&D Co., Ltd. Arylformamide compound and preparation method and medical use thereof
CN115884970A (zh) * 2020-09-24 2023-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
CA3194087A1 (en) * 2020-09-30 2022-04-07 Xuejun Zhang Benzamide compound and use thereof
CN116745284A (zh) 2020-11-27 2023-09-12 奇斯药制品公司 作为p2x3抑制剂的酞嗪衍生物
WO2022112491A1 (en) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. (aza)quinoline 4-amines derivatives as p2x3 inhibitors
MX2023005803A (es) 2020-11-27 2023-05-29 Chiesi Farm Spa Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253943A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
TW202404965A (zh) * 2022-03-29 2024-02-01 大陸商人福醫藥集團股份公司 P2x3抑制劑化合物及其鹽、多晶型和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
CA2654915C (en) 2006-06-29 2015-07-28 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
US8653091B2 (en) 2007-04-02 2014-02-18 Evotec Ag Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2008154601A1 (en) * 2007-06-12 2008-12-18 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
US8461185B2 (en) 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
KR101405746B1 (ko) 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 p2x3 및/또는 p2x2/3 퓨린성 수용체 길항제로서의 용도
BR122019016794B8 (pt) 2007-12-17 2021-07-27 Hoffmann La Roche derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
WO2009077365A1 (en) 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
EP2262766B1 (en) * 2008-02-29 2015-11-11 Evotec AG Amide compounds, compositions and uses thereof
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー P2x3受容体活性のモジュレーター
MX2011004570A (es) * 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
AU2009328347B2 (en) 2008-12-16 2016-06-09 F. Hoffmann-La Roche Ag Thiadiazole-substituted arylamides
JP5465782B2 (ja) 2009-06-22 2014-04-09 エフ.ホフマン−ラ ロシュ アーゲー 新規オキサゾロン及びピロリジノン置換アリールアミド
WO2010149578A2 (en) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel biphenyl and phenyl-pyridine amides
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
EP3998267A1 (en) 2013-01-31 2022-05-18 Bellus Health Cough Inc. Imidazopyridine compounds and uses thereof
PT3587417T (pt) 2014-12-09 2022-03-16 Bayer Ag Benzamidas substituídas por 1,3-tiazol-2-ilo
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
SG11202011010YA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
EP3757103A1 (en) 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

Also Published As

Publication number Publication date
HUE055290T2 (hu) 2021-11-29
MX2020005909A (es) 2021-10-28
LT3230281T (lt) 2021-07-12
PE20220253A1 (es) 2022-02-16
WO2016091776A1 (en) 2016-06-16
PH12017501079A1 (en) 2017-10-18
CN110256418B (zh) 2023-01-20
PT3230281T (pt) 2021-08-19
CO2017005742A2 (es) 2017-09-20
HUE058009T2 (hu) 2022-06-28
IL269467A (en) 2019-11-28
JP6544665B2 (ja) 2019-07-17
ES2882952T3 (es) 2021-12-03
MY192690A (en) 2022-09-01
AU2015359626A1 (en) 2017-06-29
UA120382C2 (uk) 2019-11-25
US10202369B2 (en) 2019-02-12
CU24411B1 (es) 2019-05-03
EP3230281B1 (en) 2021-05-26
JP6647371B2 (ja) 2020-02-14
IL269468A (en) 2019-11-28
AU2015359626B2 (en) 2020-07-23
EA201791261A1 (ru) 2017-12-29
MA41135B1 (fr) 2021-10-29
US20200131169A1 (en) 2020-04-30
US20180118731A1 (en) 2018-05-03
TW201629053A (zh) 2016-08-16
DOP2017000137A (es) 2017-07-31
MX2017007658A (es) 2018-08-01
IL283979A (en) 2021-07-29
TW202130637A (zh) 2021-08-16
KR20170093203A (ko) 2017-08-14
TN2017000244A1 (en) 2018-10-19
EP3587417B1 (en) 2022-01-05
NZ733108A (en) 2022-03-25
SV2017005461A (es) 2018-04-30
US20230053411A1 (en) 2023-02-23
IL275183B (en) 2021-06-30
US20180093980A1 (en) 2018-04-05
IL252665B (en) 2019-10-31
US10472354B2 (en) 2019-11-12
UY36422A (es) 2016-06-30
KR20230098368A (ko) 2023-07-03
ECSP17036253A (es) 2017-06-30
LT3587417T (lt) 2022-02-10
SI3230281T1 (sl) 2021-08-31
US10174016B2 (en) 2019-01-08
MA50674A (fr) 2021-03-31
IL269661A (en) 2019-11-28
DK3230281T3 (da) 2021-08-16
RS63014B1 (sr) 2022-04-29
DK3587417T3 (da) 2022-03-28
TWI780562B (zh) 2022-10-11
AR102948A1 (es) 2017-04-05
IL269661B (en) 2020-07-30
CN107207507A (zh) 2017-09-26
AR119761A2 (es) 2022-01-12
KR102548799B1 (ko) 2023-06-27
TWI716371B (zh) 2021-01-21
SG10202012274RA (en) 2021-01-28
IL269468B (en) 2020-06-30
CN110256418A (zh) 2019-09-20
SG11201704717VA (en) 2017-08-30
PL3230281T3 (pl) 2021-12-13
JOP20150301B1 (ar) 2023-09-17
MA50674B1 (fr) 2022-11-30
US11142523B2 (en) 2021-10-12
IL252665A0 (en) 2017-08-31
EA034273B1 (ru) 2020-01-23
JP2017537122A (ja) 2017-12-14
HRP20211002T1 (hr) 2021-09-17
IL269467B (en) 2020-08-31
HRP20220371T1 (hr) 2022-05-13
EA032312B1 (ru) 2019-05-31
US20190185466A1 (en) 2019-06-20
PL3587417T3 (pl) 2022-06-13
RS62227B1 (sr) 2021-09-30
CR20170242A (es) 2018-02-02
EP3587417A1 (en) 2020-01-01
EA201891120A1 (ru) 2018-10-31
CN107207507B (zh) 2020-11-06
CR20210108A (es) 2021-04-27
CA2969952A1 (en) 2016-06-16
DOP2018000182A (es) 2018-09-15
EP3230281A1 (en) 2017-10-18
IL275183A (en) 2020-07-30
NI201700073A (es) 2017-10-24
PT3587417T (pt) 2022-03-16
SI3587417T1 (sl) 2022-04-29
CU20170077A7 (es) 2017-11-07
EP3587417B9 (en) 2022-03-30
BR112017012327B1 (pt) 2023-04-11
JP2019059742A (ja) 2019-04-18
CY1125083T1 (el) 2023-06-09
PE20180227A1 (es) 2018-01-31
BR112017012327A2 (pt) 2018-02-27
BR112017012327A8 (pt) 2021-02-23
IL283979B (en) 2022-04-01
ES2908822T3 (es) 2022-05-04
CL2017001488A1 (es) 2018-02-23

Similar Documents

Publication Publication Date Title
CY1124486T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
UY35492A (es) Compuestos novedosos
PH12016501807A1 (en) Novel compounds
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CY1125085T1 (el) Αρωματικα αμιδια καρβοξυλικου οξεος ως ανταγωνιστες υποδοχεα βραδυκινινης β1
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.